Patents Assigned to SYNTARA LIMITED
  • Bioprobes for lysyl oxidases and uses thereof
    Patent number: 12578335
    Abstract: The present invention relates to novel bioprobes which are capable of binding to certain amine oxidase enzymes. These bioprobes are useful in methods of detecting and determining the concentration of certain amine oxidase enzymes in a sample as well as in methods for the quantitative assessment of inhibition of certain amine oxidases.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: March 17, 2026
    Assignee: Syntara Limited
    Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Heidi Schilter Sambade, Wenbin Zhou, Lara Anne Perryman
  • Haloallylamine dual amine oxidase inhibitors
    Patent number: 12428370
    Abstract: The present invention relates to novel compounds which are capable of inhibiting semicarbazide-sensitive amine oxidase (SSAO/VAP-1) and monoamine oxidase B (MAO-B). These compounds are useful for treatment of a variety of neuromuscular diseases, such as muscular dystrophies, and neuroinflammatory diseases, including both peripheral and central disorders in human subjects, as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: September 30, 2025
    Assignee: Syntara Limited
    Inventors: Alan Duncan Robertson, Alison Dorothy Findlay, Alberto Buson, Craig Ivan Turner, Dieter Wolfgang Hamprecht, Jonathan Stuart Foot, Mandar Deodhar, Wolfgang Jarolimek, Serena Becchi, Bernard Walter Balleine, Marcella Canton, Libero Vitiello, Bert Blaauw
  • HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF
    Publication number: 20250082593
    Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
    Type: Application
    Filed: November 21, 2024
    Publication date: March 13, 2025
    Applicant: Syntara Limited
    Inventors: Alison Dorothy FINDLAY, Craig Ivan TURNER, Mandar DEODHAR, Jonathan Stuart FOOT, Wolfgang JAROLIMEK, Wenbin ZHOU, Alberto BUSON, Angelique Elsa GRECO
  • Lysyl oxidase inhibitors for treating myeloid malignancies
    Patent number: 12233056
    Abstract: Lysyl oxidase (LOX) inhibitors, lysyl oxidase-like (LOXL) inhibitors, or pharmaceutically acceptable salts thereof and methods for the treatment of myeloid malignancies, comprising administering a therapeutically effective amount of those inhibitors alone or optionally in combination with a second therapeutic agent.
    Type: Grant
    Filed: April 5, 2023
    Date of Patent: February 25, 2025
    Assignee: Syntara Limited
    Inventors: Wolf-Karsten Hofmann, Daniel Nowak, Vladimir Ryabov, Qingyu Xu, Eva Altrock
  • Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof
    Patent number: 12178791
    Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: December 31, 2024
    Assignee: SYNTARA LIMITED
    Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alberto Buson, Angelique Elsa Greco